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Purpose
• To characterize the tolerability and PK profile of IDV 
and LPV when co-administered in ARV-experienced 
patients.  
Methods
• A 12-hour PK profile was obtained from HIV-positive 
patients taking IDV 800 mg bid and LPV/r 400/100 mg 
bid for at least 2 weeks.
• Blood was drawn immediately prior to observed PI 
administration, and then at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 
7, 8, 10 and 12 hours afterwards. 
• IDV and LPV plasma concentrations were measured by 
a sensitive and selective LC/MS/MS assay.  The LLD 
was 25 ng/mL for both drugs.  
• PK parameters were compared with data from the 
Kaletra monograph and historical data from subjects 
receiving IDV/RTV 800/100 mg bid alone. 
Results
• 5 subjects (4 M, 1 F) were included in the analysis.   
Median time on IDV & LPV/r at sampling was 3 months 
(range 1.5-8).  No patients were on concurrent NNRTI 
or other 3A4 modulating drugs.  
• All subjects had normal renal function.  One subject 
with concomitant hepatitis C had baseline AST and 
ALT twice the ULN, while the rest had normal baseline
LFTs.
Table 1: Baseline Characteristics
Demographics: Median (range)
age 47 y  (31 - 59)
viral Load log/mL 4.76  (2.89-6.00)
CD4 cells/uL 110  (10  – 607)
triglycerides mmol/L 2.32 (0.91-3.69)
cholesterol mmol/L4.42 (3.89-5.43)
Prior medication history at baseline:
# prior ARVs  9.5  (5-12)
# prior PIs  3.0  (11/21)
Results (con’t)
• Observed IDV PK parameters were comparable to 
previously published data in HIV subjects taking 
IDV 800/rtv 100 mg BID alone.  Observed LPV PK 
parameters were slightly lower than expected.
• At a median 11 months follow-up (range 5.5-21), 
no patient had discontinued therapy or undergone 
dose adjustment due to IDV- related side effects.  
There were no cases of nephrolithiasis.  One 
subject had significant lipid elevations (TG +13.35, 
TC +8.23) which responded to atorvastatin.
Conclusion
• This PK study provides evidence against the 
occurrence of a clinically significant interaction 
between IDV 800 mg and LPV/r 400/100 mg  BID.
• A larger sample size is needed to determine 
whether changes in LPV PK parameters are 
significant.
• Discontinuation of treatment associated with IDV-
specific toxicities was not observed.
Correspondence:  T. Antoniou, Pharm.D., St. Michael’s 
Hospital, 410 Sherbourne Street, 4th Floor, Toronto, 
ON  M4X 1K2, Canada.  Email:       
tantoniou@smh.toronto.on.ca
Table 2 – Median (Range) 
Indinavir and Lopinavir PK Parameters
  Cmin  
(µg/mL) 
Cmax  
(µg/mL) 
AUC[0-12] 
(µg.hr/mL) 
Indinavir:      
•  with LPV  0.61  
(0.05-1.91) 
7.58  
(5.35-9.25) 
51.84  
(29.63-64.45) 
•  800/100 
mg rtv BID
1 
0.99  
(0.58-1.4) 
8.70 
(7.5-10) 
44.0 
(29.8-58.2) 
Lopinavir:      
•  with IDV  2.90 
(0.55-4.40) 
6.30 
(4.85-8.49) 
67.91 
(43.64-78.67) 
•  alone
2 5.50  ±  4.40  9.60 ±  4.4  82.80 ±  44.50 
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